Novel 1′,1′-chain substituted Δ8-tetrahydrocannabinols
Graphic
Section snippets
Acknowledgments
This work was supported by the National Hellenic Research Foundation and by grants from the National Institute on Drug Abuse DA03801, DA09158 and DA07215. We also thank Joy Erickson for her technical support.
References (16)
Pharmacol. Ther.
(1997)- et al.
Life Sci.
(1990)Pharmacol. Rev.
(1986)et al.Chem. Phys. Lipids
(2000) - et al.
J. Med. Chem.
(1998) - et al.
J. Lab. Comp.
(1975) - et al.
Mol. Pharmacol.
(1988) - et al.
Nature
(1993) - et al.
J. Am. Chem. Soc.
(1949)et al.Bioorg. Med. Chem.
(1998)et al.J. Med. Chem.
(1996)et al.Bioorg. Med. Chem. Lett.
(1999)et al.J. Pharmacol. Exp. Ther.
(1999)et al.J. Med. Chem.
(1998)
Cited by (46)
Discovery of a CB<inf>2</inf> and 5-HT<inf>1A</inf> receptor dual agonist for the treatment of depression and anxiety
2024, European Journal of Medicinal ChemistrySynthesis and characterization of a compact tricyclic resorcinol from (+)- and (-)-3-pinanol
2012, Tetrahedron LettersCitation Excerpt :In the course of our program aimed at developing potent and selective cannabinoids we have focused on analogs with conformationally restricted and bulky side chains.5–14 In this regard, the aliphatic C3 side chain was substituted with C1′ cyclic groups,5–8 or partially immobilized by a fused six-membered ring,10,15 or replaced by the bulky adamantyl, heteroadamantyl, bornyl, and isobornyl substituents.11–14 Some of these analogs showed enhanced CB receptor subtype selectivity and affinity as well as remarkable in vivo potency.
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2
2011, European Journal of Medicinal ChemistryCitation Excerpt :A representative set of 64 CB2 ligands was selected (see Fig. 1 and Table S1), taking in no account their functional activity, among a number of 4-quinolone-3-carboxamides recently synthesized in our laboratory (23–39 and 64) [31] and derivatives belonging to different structural classes already reported in the literature (1–13, 17 and WIN55212-2 (58) [28], JWH-015 (14) and CP-55,940 (55) [32], JWH-181 (15) and JWH-007 (16) [19], AM1241 (18) [33], AM630 (19) [34], 20–22 and 40–42 [7c], 43–45 [20], L759633 (46) and L759656 (47) [35], 48–51 [21], O-1057 (52) [36], AMG41 (53) [22], JWH-133 (54) [23], AM855 (56) [24], BAY593074 (57) [37], gp1a (59) [38], 60 [39], SR144528 (61) [40], HU-308 (62) [41], and GW405833 (63) [42]). The binding affinities of all these compounds for human recombinant CB1 and CB2 receptors (Ki values) have been measured according to the same protocol, by displacement of the radioligand [3H]-CP-55,940 [7c,19–24,28,31–42] and are shown in Table 1 (second and third columns). Our selection was restrained to compounds showing high CB2 affinity (Ki values ≤ 56.7 nM) and CB1 affinity covering approximately four orders of magnitude (Ki values ranging from 0.5 to >10,000 nM).
Exploring the substituent effects on a novel series of C1′-dimethyl-aryl Δ<sup>8</sup>-tetrahydrocannabinol analogs
2008, Bioorganic and Medicinal ChemistryCombined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity
2007, Bioorganic and Medicinal Chemistry LettersBiaryl cannabinoid mimetics-Synthesis and structure-activity relationship
2007, Bioorganic and Medicinal Chemistry Letters